Market closed
Vor Biopharma/$VOR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Vor Biopharma
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Ticker
$VOR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
168
Website
Vor Biopharma Metrics
BasicAdvanced
$60M
Market cap
-
P/E ratio
-$1.65
EPS
-0.41
Beta
-
Dividend rate
Price and volume
Market cap
$60M
Beta
-0.41
52-week high
$3.14
52-week low
$0.63
Average daily volume
553K
Financial strength
Current ratio
4.691
Quick ratio
4.378
Long term debt to equity
39.327
Total debt to equity
45.033
Management effectiveness
Return on assets (TTM)
-43.51%
Return on equity (TTM)
-90.79%
Valuation
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-0.592
Growth
Earnings per share change (TTM)
-12.02%
3-year earnings per share growth (CAGR)
-17.03%
What the Analysts think about Vor Biopharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vor Biopharma stock.
Vor Biopharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Vor Biopharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Vor Biopharma News
AllArticlesVideos
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
GlobeNewsWire·2 weeks ago
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vor Biopharma stock?
Vor Biopharma (VOR) has a market cap of $60M as of December 24, 2024.
What is the P/E ratio for Vor Biopharma stock?
The price to earnings (P/E) ratio for Vor Biopharma (VOR) stock is 0 as of December 24, 2024.
Does Vor Biopharma stock pay dividends?
No, Vor Biopharma (VOR) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next Vor Biopharma dividend payment date?
Vor Biopharma (VOR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vor Biopharma?
Vor Biopharma (VOR) has a beta rating of -0.41. This means that it has an inverse relation to market volatility.